Free tool
FAERS Monitor: Menostar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021674 or its brand name (Menostar, Estradiol). Reports on generic versions are filed under their own applications.
Reports
47,042
Serious
22,534
48% of reports
Hospitalization
7,231
Death reported
909
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,830
- headache2,889
- nausea2,877
- fatigue2,870
- off label use2,399
- pain2,081
- diarrhoea1,955
- dizziness1,728
- breast cancer female1,708
- arthralgia1,636
- product adhesion issue1,582
- pruritus1,558
- rash1,538
- dyspnoea1,526
- vomiting1,348
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 524 |
| 2005 | 571 |
| 2006 | 406 |
| 2007 | 1,465 |
| 2008 | 466 |
| 2009 | 608 |
| 2010 | 958 |
| 2011 | 858 |
| 2012 | 1,156 |
| 2013 | 879 |
| 2014 | 1,113 |
| 2015 | 1,912 |
| 2016 | 2,328 |
| 2017 | 2,136 |
| 2018 | 2,487 |
| 2019 | 2,872 |
| 2020 | 2,878 |
| 2021 | 2,831 |
| 2022 | 3,054 |
| 2023 | 3,554 |
| 2024 | 3,703 |
| 2025 | 5,251 |
| 2026 | 5,031 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,007,117 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 1,708 | 30.5 | 29.0 | 45,605 |
| product adhesion issueSignal | 1,582 | 20.7 | 19.7 | 28,326 |
| headacheSignal | 2,889 | 2.1 | 2.0 | 1,627 |
| pruritus | 1,558 | 1.8 | 1.7 | 579 |
| arthralgia | 1,636 | 1.8 | 1.7 | 547 |
| fatigue | 2,870 | 1.7 | 1.6 | 761 |
| nausea | 2,877 | 1.6 | 1.6 | 720 |
| rash | 1,538 | 1.6 | 1.5 | 332 |
| dizziness | 1,728 | 1.6 | 1.5 | 345 |
| pain | 2,081 | 1.5 | 1.5 | 375 |
| diarrhoea | 1,955 | 1.4 | 1.3 | 187 |
| drug ineffective | 3,830 | 1.3 | 1.3 | 282 |
| vomiting | 1,348 | 1.3 | 1.2 | 85 |
| off label use | 2,399 | 1.2 | 1.2 | 103 |
| dyspnoea | 1,526 | 1.2 | 1.1 | 55 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.